This Week’s Biotech Highlights
Every week, I travel the world [wide web] in search of interesting new biotech developments. This week, a smattering of stories from Canada, the U.S. and China are worth noting:
In Canada (and presumably elsewhere as well) Merck put out a country-specific press release announcing the closing of its merger with Schering-Plough. Merck calls Canada “an integral part of the company’s expanded global presence.”
In the U.S., Congress decided that the shutdown of (Canada’s) Chalk River reactor was a warning, and passed a bill to stimulate domestic production of medical isotopes. About 60% of the U.S. supply had been coming from the AECL facility.
In China, all signs point to the country joining the ranks of countries advocating strong IP rights. This week, a study showed China’s research output doubling since 2004 and a Forbes article noted a copyright enforcement action by Chinese authors. Not a coincidence.
As always, there’s lots more detail at the Cross-Border Biotech Blog and on the twitter stream @crossborderbio.
SOME COMMENTS MODERATED
If you have not had an approved comment here before, your comment will be held for approval. We are glad to publish comments that address issues raised in the post or other comments on it and contribute to a fruitful discussion. We do not publish comments that seek to promote commercial products.
Although we do not require it, we ask that in making a comment you use your full name. You must supply a valid email address, which will not appear with your comment.
